Translational Research
Volume 155, Issue 3 , Pages 120-122, March 2010

Is there a role for tetrathiomolybdate in the treatment of primary biliary cirrhosis?

Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minn

Received 28 October 2009; accepted 28 October 2009. published online 03 December 2009.

Abbreviations: AMA, antimitochondrial antibody, MRS, Mayo risk score, PBC, primary biliary cirrhosis, TGF-β, transforming growth factor-β, TM, tetrathiomolybdate, TNF-α, tumor necrosis factor-α, UDCA, ursodeoxycholic acid

No abstract is available. To read the body of this article, please view the Full Text online.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S1931-5244(09)00323-5

doi:10.1016/j.trsl.2009.10.006

Translational Research
Volume 155, Issue 3 , Pages 120-122, March 2010

Article Tools